Recursion Pharmaceuticals (NASDAQ:RXRX) Stock Price Up 1.1%

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) rose 1.1% during mid-day trading on Thursday . The stock traded as high as $6.28 and last traded at $6.17. Approximately 859,079 shares were traded during mid-day trading, a decline of 86% from the average daily volume of 5,957,406 shares. The stock had previously closed at $6.10.

Analyst Ratings Changes

A number of brokerages have recently commented on RXRX. Leerink Partners cut their price objective on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a research report on Tuesday. Needham & Company LLC cut their price objective on shares of Recursion Pharmaceuticals from $16.00 to $11.00 and set a “buy” rating on the stock in a report on Wednesday. Jefferies Financial Group cut their target price on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a report on Tuesday. Finally, KeyCorp decreased their target price on shares of Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating for the company in a research report on Thursday, July 11th. Four equities research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average target price of $9.40.

Recursion Pharmaceuticals Stock Performance

The company’s fifty day simple moving average is $7.33 and its 200 day simple moving average is $8.85. The company has a current ratio of 6.07, a quick ratio of 6.07 and a debt-to-equity ratio of 0.04. The stock has a market capitalization of $1.41 billion, a P/E ratio of -3.70 and a beta of 0.82.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.05). Recursion Pharmaceuticals had a negative return on equity of 79.47% and a negative net margin of 755.37%. The business had revenue of $14.42 million for the quarter, compared to the consensus estimate of $11.96 million. During the same period in the previous year, the firm earned ($0.38) EPS. The company’s revenue was up 30.9% on a year-over-year basis. As a group, sell-side analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.6 earnings per share for the current fiscal year.

Insider Buying and Selling at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction on Tuesday, June 25th. The shares were sold at an average price of $9.51, for a total value of $108,860.97. Following the completion of the transaction, the director now owns 7,177,116 shares of the company’s stock, valued at $68,254,373.16. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. In related news, Director Blake Borgeson sold 11,447 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Tuesday, June 25th. The shares were sold at an average price of $9.51, for a total value of $108,860.97. Following the completion of the sale, the director now owns 7,177,116 shares in the company, valued at approximately $68,254,373.16. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Michael Secora sold 15,000 shares of the business’s stock in a transaction on Thursday, June 13th. The stock was sold at an average price of $9.32, for a total transaction of $139,800.00. Following the completion of the transaction, the chief financial officer now owns 1,243,468 shares of the company’s stock, valued at approximately $11,589,121.76. The disclosure for this sale can be found here. In the last quarter, insiders have sold 243,129 shares of company stock valued at $1,807,845. Company insiders own 15.75% of the company’s stock.

Institutional Investors Weigh In On Recursion Pharmaceuticals

Several hedge funds have recently made changes to their positions in RXRX. Benjamin F. Edwards & Company Inc. purchased a new position in shares of Recursion Pharmaceuticals during the 1st quarter worth approximately $26,000. National Bank of Canada FI lifted its holdings in shares of Recursion Pharmaceuticals by 90.9% during the 4th quarter. National Bank of Canada FI now owns 3,150 shares of the company’s stock valued at $31,000 after acquiring an additional 1,500 shares in the last quarter. GAMMA Investing LLC increased its stake in Recursion Pharmaceuticals by 1,588.4% during the 2nd quarter. GAMMA Investing LLC now owns 6,416 shares of the company’s stock worth $48,000 after buying an additional 6,036 shares during the period. Amalgamated Bank increased its stake in Recursion Pharmaceuticals by 52.4% during the 2nd quarter. Amalgamated Bank now owns 7,152 shares of the company’s stock worth $54,000 after buying an additional 2,459 shares during the period. Finally, Midwest Financial Group LLC bought a new stake in shares of Recursion Pharmaceuticals in the 2nd quarter worth about $90,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.